Pasithea Therapeutics Progresses with PAS-004 in Cancer Trials

Pasithea Therapeutics Moves Forward with PAS-004

Pasithea Therapeutics Corp. (NASDAQ: KTTA) has received encouraging feedback from the external Safety Review Committee regarding their ongoing Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor. The committee recommended progressing to the next dose level of 15mg capsules, marking a significant step forward for the company.

Through careful observation, the committee noted that there have been no dose-limiting toxicities (DLTs) reported so far, which supports their decision to escalate the dosage. Furthermore, the absence of rash, a common side effect seen with other MEK inhibitors, adds to the promising safety profile of PAS-004.

Trial Highlights and Safety Observations

Dr. Tiago Reis Marques, the CEO of Pasithea, expressed enthusiasm over the trial results, highlighting the lack of rash among the initial nine participants receiving PAS-004. This is particularly noteworthy, as competitor MEK inhibitors often lead to rashes at lower doses, contributing to higher discontinuation rates in clinical settings. Additionally, the company has chosen to expand the trial by introducing a cohort 4b, which will involve three more patients and include an alternative formulation intended for commercial use.

Clinical Trial Overview

The Phase 1 clinical trial is designed as a multi-center, open-label, dose-escalation study utilizing a 3+3 design to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of PAS-004 in patients diagnosed with advanced solid tumors driven by MAPK pathway mutations. This includes patients with documented RAS, NF1, or RAF mutations, as well as those who have previously failed BRAF/MEK inhibition.

PAS-004: A New Approach to MEK Inhibition

PAS-004 stands out among first-generation MEK inhibitors by potentially allowing for once-daily dosing due to its long half-life of approximately 70 hours. In contrast, traditional inhibitors often require twice-daily dosing and present short half-lives of less than eight hours. This unique pharmacokinetic profile presents an opportunity to maintain consistent plasma levels, ultimately mitigating the risks associated with peak-related toxicity. These advantages provide a strong rationale for advancing PAS-004 in clinical studies for treating both cutaneous and plexiform neurofibromas in Neurofibromatosis type 1 (NF1) and other cancer indications.

Future Directions for Pasithea Therapeutics

As the clinical trial progresses, Pasithea Therapeutics intends to share periodic updates, announcing any new findings that articulate the safety and efficacy of PAS-004. With a growing emphasis on innovative therapies for CNS disorders and RASopathies, the company continues to focus on developing new treatment options for conditions such as NF1 and Amyotrophic Lateral Sclerosis (ALS).

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company dedicated to the research and discovery of advanced treatments for various neurological disorders and cancer conditions. With an expert team specializing in neuroscience and drug development, the company aims to innovate therapies tailored for unmet medical needs in the field of oncology and not just CNS disorders.

Frequently Asked Questions

What is PAS-004?

PAS-004 is a next-generation macrocyclic MEK inhibitor developed by Pasithea Therapeutics, aimed at treating advanced solid tumors and neurofibromatosis type 1 (NF1).

What were the results from the latest clinical trial updates?

The latest updates indicate no observed dose-limiting toxicities and a lack of rash in patients, leading to the committee's recommendation to escalate to a higher dose of 15mg.

What is the significance of the Safety Review Committee's recommendation?

The recommendation to proceed to the next dose level reflects confidence in the drug’s safety profile, suggesting promising results that could lead to further development.

How does PAS-004 compare to first-generation MEK inhibitors?

PAS-004 may offer prolonged target inhibition with once-daily dosing, unlike first-generation inhibitors that typically require more frequent dosing and may lead to higher rates of adverse effects.

What are the goals for Pasithea Therapeutics in the future?

Pasithea aims to advance their clinical trials, continuously improve treatment options for cancer and CNS disorders, and eventually bring new therapies to market.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.